Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

Key Inclusion Criteria: * Life expectancy ≥ 3 months. * Pathologically documented NSCLC that meets both of the criteria below: * Have documented evidence of Stage IV NSCLC disease at the time of enrollment (based on American Joint Committee on Cancer (AJCC), Eighth Edition). * Have documented negative test results for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations. * Have no actionable genomic alterations such as ROS proto-oncogene 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), proto-oncogene B-raf (BRAF), RET mutations, or other driver oncogenes with approved frontline therapies. * Have not received prior systemic treatment for metastatic NSCLC. * Measurable disease per RECIST v1.1 criteria by investigator assessment. * Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1. * Have adequate organ functions. Key Exclusion Criteria: * Have mixed small-cell lung cancer (SCLC) and NSCLC histology. * Positive serum pregnancy test or individuals who are breastfeeding or have plans to breastfeed during the study period. * Received prior treatment with any anti-PD-1, anti-PD-L1, or any other antibody targeting an immune checkpoint. * Known hypersensitivity to the study drug, its metabolites, or formulation excipient. * Have an active second malignancy or have had an active second malignancy within 3 years prior to enrollment. * Have an active autoimmune disease that required systemic treatment in past …